Abstract：Objective To investigate the status and influencing factors of medication adherence among hepatitis B patients in the middle and later period of pregnancy. Methods A total of 124 hepatitis B patients in the middle and later period of pregnancy treated in the Fifth Hospital of Shijiazhuang City from April 2016 to April 2017 were recruited. Medication adherence was assessed by the Morisky Medication Adherence Questionnaire (MAQ). The main measuring instruments included the general Characteristics Questionnaire, the hepatitis B knowledge questionnaire and the Medication belief scale. Multiple Logistic regression analysis was used to analyze the influencing factors of medication adherence of hepatitis B patients. Results The score of overall hepatitis B related knowledge, the Medication belief and medication adherence were fair to middling, and the patients with good compliance accounted for 60.5%(75 cases). Multivariate Logistic regression analysis showed that education level (OR = 0.578, 95%CI: 0.104-0.877), parents have or no hepatitis B (OR = 0.392, 95%CI: 0.177-0.631), diagnosis time of hepatitis B (OR = 3.998, 95%CI: 1.188-5.285), hepatitis B related knowledge (OR = 0.746, 95%CI: 0.389-0.847), medication beliefs (OR = 0.787, 95%CI: 0.259-0.977) were influencing factors for medication adherence (P < 0.05). Conclusion Health care workers should combine the influencing factors of medication adherence to carry out targeted health education, so as to improve their medication adherence and reduce the vertical transmission rate of hepatitis B.
杜晓娜 田红卫 吴惠萍 董佳伟 刘晓静 董正洪. 孕中晚期乙肝患者抗病毒治疗服药依从性及影响因素[J]. 中国医药导报, 2018, 15(23): 71-75.
DU Xiaona TIAN Hongwei WU Huiping DONG Jiawei LIU Xiaojing DONG Zhenghong. Medication adherence and its influencing factors among the hepatitis B patients in the middle and later period of pregnancy. 中国医药导报, 2018, 15(23): 71-75.
[1] 郭燕.武汉市乙肝母婴传播阻断措施及效果评价研究[D].武汉：华中科技大学，2009.
[2] World Health Organigzotion.全球肝炎报告，2017[R].WHO.2017.
[3] 中国疾病预防控制中心.中国法定传染病发病与死亡报告[R].北京：中国疾病预防控制中心，2010：50-55.
[4] Koedijk FD，op de Coul EL，Boot HJ，et al. Hepatitis B surveillance in the Netherlands，2002-2005：acute infection is mainly via sexual contact while chronic infection is via vertical transmission through mothers from endemicregions [J]. Ned Tijdschr Geneeskd，2007，151（43）：2389-2394.
[5] 陈天艳，刘敏，陈云茹，等.宫内传播的研究进展[J].世界华人消化杂志，2007，15（19）：2138-2143.
[6] 张丽菊，王玲.替比夫定对妊娠后期乙型肝炎病毒宫内感染的阻断作用[J].中华肝脏病杂志，2009，17（8）：561-563．
[7] 韩国荣，江红秀，王根菊，等．替比夫定对乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J].中华肝脏病杂志，2012，3，20（3）：201-205．
[8] Han GＲ，Cao MK，Zhao W，et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection [J]. J Hepatol，2011，55（6）：1215-1221．
[9] 戴俊明，卫志华，张蓓燕，等.社区高血压病人药物治疗依从性与影响因素分析[J].中国慢性病预防与控，2000， 8（6）：253-255.
[10] 李秋云，张静，张欣.乙肝病毒携带产妇掌握母婴阻断知识的调查[J].中华现代护理杂志，2011，17（36）：4482-4484.
[11] Sabate E. Adherence to long-term therapies：evidence for action [M]. Geneva：World Health Organization，2003：17-19.
[12] 周达生，姚华庭.医学系统工程与遵医行为研究[J].中国医院管理，1995（2）：37-39.
[13] 邓润泽.成渝两地社区居民乙肝、丙肝知信行的流行病学调查[D].重庆：重庆医科大学，2017.
[14] 黄晓华.乙型病毒性肝炎免疫预防的现状调查[J].中国医药指南，2012，10（4）：104-105.
[15] 张晓红，张缭云.山西省77个家庭家族性乙型肝炎临床流行病学调查[J].中华流行病学杂志，2008，2（4）：412.
[16] 朱桂兰.对乙型肝炎病毒母婴传播阻断的护理干预[J].青海医药，2007（8）：55-56.
[17] 柏亚妹，宋玉磊，卞秋桂，等.炎症性肠病患者服药依从性及其影响因素研究[J].中国全科医学，2017（32）.
[18] Watt MH，Maman S，Earp JA，et al. “Its all the time in my mind”：Facilitators of adherence to antiretroviral therapy in a Tanzanian setting [J]. Social science & medicine，2009，68（10）：1793-1800.
[19] 黄敬亨.健康教育学[M].3版.上海：复旦大学出版社，2002：28-34.
[20] 朱启镕.重视与加强乙型肝炎病毒母婴传播的研究[J].中华儿科杂志，2006，44（12）：883-885.
2018, Vol. 15 
京公网安备 11010502046598号